文献速递新发突发、热带与寄生虫病细菌感染、耐药与抗菌药物

孟德尔随机化在感染性疾病中的应用:陷阱与前景

Mendelian Randomization and Infection: Pitfalls and Promises.
PubMed 文献 · J Infect Dis · 2025-01-01

本文综述了孟德尔随机化(MR)在感染性疾病(ID)研究中的原理、假设与特定挑战,指出以感染为暴露的MR研究比以感染为结局的研究更易产生偏倚,并强调MR应恰当地用于回答其他方法无法解决的因果问题。

要点

  • MR在感染性疾病中应用日增,有望识别感染的因果与后果并提示药物靶点。
  • 许多MR应用因违反核心假设而结果无法解释。
  • 以感染为暴露的MR研究比以感染为结局者更易产生偏倚。

核心结论

  • MR在感染性疾病中具有前景,但当前许多应用因违反核心假设而提供有限见解并产生无法解释的结果。

研究设计与样本

  • 本文为综述,回顾MR的原理、假设及在感染性疾病中的特定挑战。

主要发现

  • MR可识别传统流行病学难以解决的感染因果与后果,并提示合理药物靶点,如COVID-19试验中的baricitinib和tocilizumab。
  • 以感染为暴露的MR研究比以感染为结局的研究更易产生偏倚。

临床怎么用

  • MR应恰当地应用于回答其他方法无法解决的因果问题,并利用新兴机会提供独特见解。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mendelian randomization (MR) is an increasingly common study design in infectious diseases (ID). It holds promise for identifying causes and consequences of infections where conventional epidemiology has struggled, and can highlight plausible drug targets, as shown in successful coronavirus disease 2019 (COVID-19) trials (baricitinib, tocilizumab). However, many current applications provide limited insight due to violations of core assumptions, yielding uninterpretable results. This article reviews MR principles, assumptions, and specific challenges in ID. We highlight examples violating key assumptions, noting that MR studies using infection as an exposure are particularly prone to bias compared to using infection as an outcome. We discuss the future of MR in ID, emphasizing appropriate application to address causal questions unanswerable by other methods and capitalize on emerging opportunities where MR can provide unique insights.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hamilton F, Butler-Laporte G, Davey Smith G, et al. Mendelian Randomization and Infection: Pitfalls and Promises. J Infect Dis. 2025. PMID: 40435229. doi:10.1093/infdis/jiaf251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。